US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

AI Healthcare

577.53

-1.9673-0.34%

Number of Gainers:1

Number of Losers:3

Number of Flat:- -

PE:- -

High:594.94

Open:579.85

Low:571.34

Close:579.50

Loading ...

2 Beaten-Down Stocks With Incredible Upside Potential

Tempus Publishes Study Validating the Benefits of xF+, its Comprehensive Liquid Biopsy Assay for Therapy Selection

Recursion Pharmaceuticals (RXRX) Surpasses Market Returns: Some Facts Worth Knowing

tempus AI Inc Class A call volume above normal and directionally bullish

Analysts Split on High-Stakes ‘Call Option’ for Tempus AI Stock (TEM)

Tempus Introduces Loop, an AI-Powered Target Discovery and Validation Platform

Press Release: Recursion to Report First Quarter 2025 Business Updates and Financial Results on May 5th

Why Tempus AI Inc. (TEM) Soared Last Week

US Health Secretary Reportedly Says 35 States to Join Pilot Program for Sickle Cell Disease Gene Therapies

MT Newswires Live

Press Release: Tempus to Report First Quarter 2025 Financial Results on May 6

Tempus AI Stock (TEM) Surges over 14% in a Day – What’s Next for Investors?

Tempus AI, Inc. (TEM): A Bull Case Theory

Tempus AI Shares Soared 14% After Deals With AstraZeneca, Pathos AI

Why Tempus AI Inc. (TEM) Went Up On Wednesday

CRISPR Therapeutics AG (CRSP) Stock Falls Amid Market Uptick: What Investors Need to Know

Is Tempus AI, Inc. (TEM) the Best Nancy Pelosi Stock To Invest In Now?

BRIEF-Tempus AI Inc Announces Strategic Collaborations With AstraZeneca And Pathos

Recursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025

Crispr Therapeutics AG: Promising Growth with Casgevy Launch and Innovative Pipeline

Recursion Pharmaceuticals (RXRX) Stock Moves -1.64%: What You Should Know

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK4611/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4611","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4611\",,,,,undefined,":{"symbol":"BK4611","market":"US","secType":"PLATE","nameCN":"AI Healthcare","latestPrice":577.5325,"timestamp":1745956799999,"preClose":579.4998,"halted":0,"volume":23341416,"delay":0,"changeRate":-0.003395,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":-1.967346,"latestTime":"04-29 16:00:00 EDT","open":579.8532,"high":594.9411,"low":571.3403,"amount":675923323.813768,"amplitude":0.040726,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1746019800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":4.489199,"peRate":-8.818352,"turnoverRate":0.035458,"increases":1,"decrements":3,"flats":0,"marketCap":16907000448,"floatMarketCap":12560520832},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4611\",,,,,undefined,":{"symbol":"BK4611","high":594.9411,"amplitude":0.040726,"preClose":579.4998,"low":571.3403,"pbRate":"4.489199","latestPrice":577.5325,"volume":23341416,"delay":0,"open":579.8532,"prevYearClose":530.4984,"prevWeekClose":573.8122,"prevMonthClose":527.803,"prevQuarterClose":527.803,"fiveDayClose":529.7714,"twentyDayClose":527.803,"sixtyDayClose":651.3898,"secType":"PLATE","market":"US","turnoverRate":0.035458,"peRate":-8.818352,"marketCap":16907000448,"floatMarketCap":12560520832,"timestamp":1745956799999,"nameCN":"AI Healthcare"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4611\",,,,undefined,":{"bkCode":"BK4611","up":1,"down":3,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4611\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2531700701","title":"2 Beaten-Down Stocks With Incredible Upside Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2531700701","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531700701?lang=en_us&edition=fundamental","pubTime":"2025-04-30 17:14","pubTimestamp":1746004440,"startTime":"0","endTime":"0","summary":"Iovance Biotherapeutics' lead medicine is generating growing sales and seeking plenty of label expansions.CRISPR Therapeutics has exciting gene-editing candidates in the works.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/04/30/2-beaten-down-stocks-with-incredible-upside-potent/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["LU1861558580.USD","IPO","CRSP","LU1861559042.SGD","BK4139","BK4611","BK4585","BK4588","BK4556"],"gpt_icon":0},{"id":"2531973698","title":"Tempus Publishes Study Validating the Benefits of xF+, its Comprehensive Liquid Biopsy Assay for Therapy Selection","url":"https://stock-news.laohu8.com/highlight/detail?id=2531973698","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531973698?lang=en_us&edition=fundamental","pubTime":"2025-04-29 20:30","pubTimestamp":1745929800,"startTime":"0","endTime":"0","summary":"The validation study recently published in the Journal of Molecular Diagnostics. CHICAGO, April 29, 2025----Tempus AI, Inc. , a technology company leading the adoption of AI to advance precision medicine and patient care, today announced publication of its study, \"Analytical Validation of NGS-based Comprehensive Liquid Biopsy Assay for Therapy\" in the Journal of Molecular Diagnostics. Data from this study supports the utility of xF+ as a non-invasive technique to detect actionable variants including resistance mutations, identify clinically relevant biomarkers, and monitor disease progression.The xF+ assay integrates with the Tempus multimodal database, supporting therapeutic recommendations and clinical research. Originally introduced in 2022, the xF+ panel covers 523 genes spanning ~1.8 Mb of the human genome. The validation study shows that the xF+ assay shows concordance with the Tempus xF and xT assays for MSI status and gene coverage. The assay exhibits accuracy, sensitivity, spe","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tempus-publishes-study-validating-benefits-123000329.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4121","LU1861558580.USD","BK4611","TEM","BK4613","LU1861559042.SGD"],"gpt_icon":1},{"id":"2531296670","title":"Recursion Pharmaceuticals (RXRX) Surpasses Market Returns: Some Facts Worth Knowing","url":"https://stock-news.laohu8.com/highlight/detail?id=2531296670","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531296670?lang=en_us&edition=fundamental","pubTime":"2025-04-29 05:50","pubTimestamp":1745877015,"startTime":"0","endTime":"0","summary":"The most recent trading session ended with Recursion Pharmaceuticals  standing at $5.84, reflecting a +1.83% shift from the previouse trading day's closing. The stock outpaced the S&P 500's daily gain of 0.06%. Elsewhere, the Dow gained 0.28%, while the tech-heavy Nasdaq lost 0.1%.The biotechnology company's stock has dropped by 1.38% in the past month, exceeding the Medical sector's loss of 6.38% and the S&P 500's loss of 4.29%.Investors will be eagerly watching for the performance of Recursion Pharmaceuticals in its upcoming earnings disclosure. The company is expected to report EPS of -$0.44, down 12.82% from the prior-year quarter. In the meantime, our current consensus estimate forecasts the revenue to be $20.15 million, indicating a 46.12% growth compared to the corresponding quarter of the prior year.It is also important to note the recent changes to analyst estimates for Recursion Pharmaceuticals. These latest adjustments often mirror the shifting dynamics of short-term busines","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/recursion-pharmaceuticals-rxrx-surpasses-market-215015830.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4539","BK4139","BK4609","BK4548","BK4611","RXRX"],"gpt_icon":1},{"id":"2531317222","title":"tempus AI Inc Class A call volume above normal and directionally bullish","url":"https://stock-news.laohu8.com/highlight/detail?id=2531317222","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531317222?lang=en_us&edition=fundamental","pubTime":"2025-04-28 23:45","pubTimestamp":1745855106,"startTime":"0","endTime":"0","summary":"Bullish option flow detected in tempus AI (TEM) Inc Class A with 23,202 calls trading, 3x expected, and implied vol increasing almost 2 points to 1...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tempus-ai-inc-class-a-call-volume-above-normal-and-directionally-bullish-7?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tempus-ai-inc-class-a-call-volume-above-normal-and-directionally-bullish-7?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4611","BK4613","BK4121","LU1861559042.SGD","TEM","LU1861558580.USD"],"gpt_icon":0},{"id":"2530239171","title":"Analysts Split on High-Stakes ‘Call Option’ for Tempus AI Stock (TEM)","url":"https://stock-news.laohu8.com/highlight/detail?id=2530239171","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530239171?lang=en_us&edition=fundamental","pubTime":"2025-04-28 23:25","pubTimestamp":1745853957,"startTime":"0","endTime":"0","summary":"Tempus AI ($TEM) stock rallied after revealing a multi-year, strategic collaboration with AstraZeneca ($AZN) and Pathos AI. The deal represents an ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/analysts-split-on-high-stakes-call-option-for-tempus-ai-stock-tem?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/analysts-split-on-high-stakes-call-option-for-tempus-ai-stock-tem?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4611","LU1861558580.USD","BK4121","LU1861559042.SGD","TEM","BK4613"],"gpt_icon":0},{"id":"2530402727","title":"Tempus Introduces Loop, an AI-Powered Target Discovery and Validation Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2530402727","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530402727?lang=en_us&edition=fundamental","pubTime":"2025-04-28 20:30","pubTimestamp":1745843400,"startTime":"0","endTime":"0","summary":"The new, proprietary target discovery platform integrates RWD, human biological modeling, and CRISPR screens to accelerate novel target identification. One of the biggest industry challenges has been translating promising preclinical experiments into treatments that can benefit patients. Conventional approaches in target discovery and validation rely on cell lines or animal models, which may not be reliable representations of human tumors. Loop’s approach is uniquely powerful because it leverages Tempus’ rich RWD to identify patient subpopulations with similar clinical, pathologic, and molecular patterns, followed by use of systems biological approaches to help reveal novel target genes and multimodal signatures. These signatures allow Tempus to seamlessly map patient subcohorts to relevant patient-derived organoids , which the company has been expanding for years. By ensuring continuity between RWD and PDOs, Tempus can validate targets using high-throughput functional screens in model","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tempus-introduces-loop-ai-powered-123000978.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1861559042.SGD","BK4613","TEM","BK4121","BK4611","LU1861558580.USD"],"gpt_icon":1},{"id":"2530440159","title":"Press Release: Recursion to Report First Quarter 2025 Business Updates and Financial Results on May 5th","url":"https://stock-news.laohu8.com/highlight/detail?id=2530440159","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530440159?lang=en_us&edition=fundamental","pubTime":"2025-04-28 20:27","pubTimestamp":1745843220,"startTime":"0","endTime":"0","summary":"Company to host public earnings call on May 5th at 8:00 am ET / 6:00 am MT / 1:00 pm GMT. Salt Lake City, UT, April 28, 2025  -- Recursion , a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will provide business updates and report its first quarter 2025 financial results on Monday, May 5, 2025, before the open of the financial markets.Recursion  is a clinical stage TechBio company leading the space by decoding biology to radically improve lives. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously generate one of the world's largest proprietary biological and chemical datasets. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. By commanding massive experimental scale -- up to millions of wet lab experiments weekly -- and massive c","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4611","BK4539","L","BK4588","BK4609","BK4548","RXRX","BK4585","BK4107","LU0053666078.USD"],"gpt_icon":0},{"id":"2530175339","title":"Why Tempus AI Inc. (TEM) Soared Last Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2530175339","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530175339?lang=en_us&edition=fundamental","pubTime":"2025-04-27 02:04","pubTimestamp":1745690649,"startTime":"0","endTime":"0","summary":"We recently published a list of Why These 10 Firms Recorded Double-Digit Gains Last Week. In this article, we are going to take a look at where Tempus AI Inc.  stands against other firms that recorded double-digit gains last week.Ten companies finished the past trading week on a high note, outperforming the three major indices with double-digit gains amid a flurry of catalysts, including upcoming earnings releases, that sparked buying appetite.Week-on-week, the Nasdaq rallied by 6.7 percent, the S&P 500 clocked in a 4.59-percent gain, while the Dow Jones was up by 2.48 percent.In other news, Tempus AI Inc.  clinched a new $200-million deal with AstraZeneca and Pathos AI for the development of a multimodal foundation model in oncology. The total amount includes data licensing and model development fees.Overall, TEM ranks 4th on our list of firms that recorded double-digit gains last week. While we acknowledge the potential of TEM as an investment, our conviction lies in the belief that ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-tempus-ai-inc-tem-180409062.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["QID","LU1861558580.USD","BK4613","NVIW.SI","MNQmain","BK4121","NQmain","USJW.SI","LU1861559042.SGD","USAW.SI","TQQQ","TEM","SQQQ","QLD",".IXIC","BK4611","PSQ","TSYW.SI"],"gpt_icon":1},{"id":"2530643321","title":"US Health Secretary Reportedly Says 35 States to Join Pilot Program for Sickle Cell Disease Gene Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2530643321","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530643321?lang=en_us&edition=fundamental","pubTime":"2025-04-26 03:19","pubTimestamp":1745608779,"startTime":"0","endTime":"0","summary":"US Health and Human Services Secretary Robert Kennedy Jr. said 35 states will participate in a federal pilot program to expand access of costly gene therapies for sickle cell disease to Medicaid patients, multiple news outlets reported Friday.These 35 states house almost 84% of the Medicaid patients with the genetic blood disorder, Bloomberg reported, citing Kennedy's speech to the National Council of Insurance Legislators.The pilot program would also allow the Centers for Medicare and Medicaid Services to arrange payment agreements for the therapies on behalf of states, Bloomberg said.The various states' interest in the pilot program represents \"positive news\" for pharmaceutical companies that manufacture the gene therapies, including Bluebird Bio , Vertex Pharmaceuticals  and Crispr Therapeutics . The companies' therapies, which were approved in December 2023, come with a costly price tag and \"have struggled to gain traction,\" according to Bloomberg.The Department of Health and Human","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1035775433.USD","LU0289739699.SGD","LU1093756325.SGD","BK4611","LU2362541273.HKD","BK4139","IE00B19Z9P08.USD","CRSP","LU0256863811.USD","LU1430594728.SGD","IE00B4R5TH58.HKD","IE00B2B36J28.USD","LU2462157665.USD","LU2417539215.USD","LU1861559042.SGD","IE00BFTCPJ56.SGD","SG9999013999.USD","BK4533","BLUE","IE00B19Z3B42.SGD","LU1861558580.USD","SG9999001176.SGD","VRTX","LU0889565916.HKD","LU1585245621.USD","IE00BZ9MQY76.HKD","BK4585","LU0234570918.USD","IE0002270589.USD","LU0417517546.SGD","LU2236285917.USD","LU0320765992.SGD","BK4578","LU1093756168.USD","IE00B19Z9Z06.USD","SGXZ57979304.SGD","IE00BJT1NW94.SGD","LU0079474960.USD","BK4567","IE00B19Z3581.USD","IE00B894F039.SGD","LU0109394709.USD","LU0823416689.USD","IE0002141913.USD","LU2324357040.USD","LU0058720904.USD","LU2456880835.USD","LU2237438978.USD","LU0061475181.USD","BK4556"],"gpt_icon":0},{"id":"2529898436","title":"Press Release: Tempus to Report First Quarter 2025 Financial Results on May 6","url":"https://stock-news.laohu8.com/highlight/detail?id=2529898436","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529898436?lang=en_us&edition=fundamental","pubTime":"2025-04-24 20:33","pubTimestamp":1745497980,"startTime":"0","endTime":"0","summary":"Tempus AI, Inc. , a leader in artificial intelligence and precision medicine, today announced they will report financial results for the first quarter of 2025 on Tuesday, May 6, 2025. The company will hold the earnings conference call at 4:30 p.m. ET. The company's quarterly earnings will be released the same day.The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Alternatively, the call can be accessed via the following:. Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world's largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, developm","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TEM","BK4613","BK4611","BK4121","LU1861559042.SGD","LU1861558580.USD"],"gpt_icon":1},{"id":"2529061605","title":"Tempus AI Stock (TEM) Surges over 14% in a Day – What’s Next for Investors?","url":"https://stock-news.laohu8.com/highlight/detail?id=2529061605","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529061605?lang=en_us&edition=fundamental","pubTime":"2025-04-24 18:14","pubTimestamp":1745489672,"startTime":"0","endTime":"0","summary":"Tempus AI ($TEM) has seen a significant surge on Wednesday, with its stock climbing 14.62% in just one day. The significant boost in TEM stock foll...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/tempus-ai-stock-tem-surges-over-14-in-a-day-whats-next-for-investors?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/tempus-ai-stock-tem-surges-over-14-in-a-day-whats-next-for-investors?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4211","ISBC","BK4611","BK4613","LU1861558580.USD","LU1861559042.SGD","BK4121","TEM"],"gpt_icon":0},{"id":"2529699661","title":"Tempus AI, Inc. (TEM): A Bull Case Theory","url":"https://stock-news.laohu8.com/highlight/detail?id=2529699661","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529699661?lang=en_us&edition=fundamental","pubTime":"2025-04-24 07:59","pubTimestamp":1745452746,"startTime":"0","endTime":"0","summary":"We came across abullish thesison Tempus AI, Inc.  on Substack by Oliver | MMMT Wealth. In this article, we will summarize the bulls’ thesis on TEM. Tempus AI, Inc. 's share was trading at $43.23 as of April 22nd.Tempus AI, Inc.  is not on our list of the30 Most Popular Stocks Among Hedge Funds. As per our database, 17 hedge fund portfolios held TEM at the end of the fourth quarter which was 7 in the previous quarter. While we acknowledge the risk and potential of TEM as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than TEM but that trades at less than 5 times its earnings, check out our report about thecheapest AI stock.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tempus-ai-inc-tem-bull-235906629.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1861558580.USD","LU1861559042.SGD","BK4611","BK4613","BK4121","TEM"],"gpt_icon":1},{"id":"2529265833","title":"Tempus AI Shares Soared 14% After Deals With AstraZeneca, Pathos AI","url":"https://stock-news.laohu8.com/highlight/detail?id=2529265833","media":"Dow Jones","labels":["corporation","movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529265833?lang=en_us&edition=fundamental","pubTime":"2025-04-24 07:48","pubTimestamp":1745452093,"startTime":"0","endTime":"0","summary":"Tempus AI shares were 14% higher, at $49.35, after the company said it has entered into multi-year strategic collaborations with AstraZeneca and Pathos AI.The technology company said the companies will work together to build a multimodal foundation model in oncology which can be used to gather biological and clinical insights, discover novel drug targets and develop therapeutics for the broader oncology community.The agreements include $200 million in data licensing and model development fees to Tempus.Tempus said its de-identified oncology data will be used to build the foundation model. Upon completion, the model will be shared among all three parties to advance their individual efforts to improve patient care.Tempus stock hit its 52-week high of $91.45 on Feb. 14, and are up 48% year-to-date.","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Tempus AI Shares Soared 14% After Deals With AstraZeneca, Pathos AI","news_tag":"corporation,movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4611","BK4121","BK4613","LU1861558580.USD","LU1861559042.SGD","TEM"],"gpt_icon":1},{"id":"2529629886","title":"Why Tempus AI Inc. (TEM) Went Up On Wednesday","url":"https://stock-news.laohu8.com/highlight/detail?id=2529629886","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529629886?lang=en_us&edition=fundamental","pubTime":"2025-04-24 06:16","pubTimestamp":1745446610,"startTime":"0","endTime":"0","summary":"Wall Street’s major indices rebounded anew on Wednesday as worries about tariff policies and the Federal Reserve’s independence tapered off after President Donald Trump assured that he had no intentions of ousting Jerome Powell.The Nasdaq surged by 2.5 percent, the S&P 500 rose by 1.67 percent, while the Dow Jones increased by 1.07 percent.Ten companies mirrored the broader market optimism as optimistic investors resumed pouring funds into their stocks. In this article, we have identified Wednesday’s 10 best-performing stocks during the intra-day trading and detailed the reasons behind their strong performance.To come up with the list, we considered only the stocks with more than $2 billion in market capitalization and $5 million in intraday trading volume.A healthcare provider holding an MRI scan of a patient with a traumatic brain injury.READ NEXT: 20 Best AI Stocks To Buy Nowand30 Best Stocks to Buy Now According t","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-tempus-ai-inc-tem-221650483.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1861559042.SGD","TEM","BK4121","BK4613","LU1861558580.USD","BK4611"],"gpt_icon":1},{"id":"2529469505","title":"CRISPR Therapeutics AG (CRSP) Stock Falls Amid Market Uptick: What Investors Need to Know","url":"https://stock-news.laohu8.com/highlight/detail?id=2529469505","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529469505?lang=en_us&edition=fundamental","pubTime":"2025-04-24 06:00","pubTimestamp":1745445615,"startTime":"0","endTime":"0","summary":"In the latest trading session, CRISPR Therapeutics AG  closed at $38.54, marking a -1.76% move from the previous day. This change lagged the S&P 500's daily gain of 1.67%. Elsewhere, the Dow saw an upswing of 1.07%, while the tech-heavy Nasdaq appreciated by 2.5%.Coming into today, shares of the company had lost 4.06% in the past month. In that same time, the Medical sector lost 9.34%, while the S&P 500 lost 6.57%.Market participants will be closely following the financial results of CRISPR Therapeutics AG in its upcoming release. In that report, analysts expect CRISPR Therapeutics AG to post earnings of -$1.27 per share. This would mark year-over-year growth of 11.19%. Meanwhile, the latest consensus estimate predicts the revenue to be $5.24 million, indicating a 947.2% increase compared to the same quarter of the previous year.Any recent changes to analyst estimates for CRISPR Therapeutics AG should also be noted by investors. These latest adjustments often mirror the shifting dynami","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/crispr-therapeutics-ag-crsp-stock-220015781.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4210","BK4588","BK4211","CRSP","AG","BK4585","ISBC","LU1861558580.USD","LU1861559042.SGD","BK4556","BK4611","BK4139"],"gpt_icon":0},{"id":"2529565426","title":"Is Tempus AI, Inc. (TEM) the Best Nancy Pelosi Stock To Invest In Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2529565426","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529565426?lang=en_us&edition=fundamental","pubTime":"2025-04-24 01:26","pubTimestamp":1745429209,"startTime":"0","endTime":"0","summary":"We recently published a list of 15 Best Nancy Pelosi Stocks To Invest In Now. In this article, we are going to take a look at where Tempus AI, Inc.  stands against other best Nancy Pelosi stocks to invest in now.We are aware that Nancy Pelosi isn’t the only member of the Congress with amazing stock picking ability. And wouldn’t you know it, fresh-faced financial geniuses like Marjorie Taylor Green are popping up, conveniently dumping Treasuries to load up on tech stocks just before a tariff pause. Green sold around $75000  of US Treasury bills to fund purchases of more than a dozen stocks  before Trump’s temporary tariff pause announcement. We published the list of her stock picks in20 Best Stocks to Buy According to Marjorie Taylor Greene.For this article, we consulted Capitol Trades, a platform that tracks the stock trading activity of politicians in the United States. It is important to clarify that the stocks listed below were picked from the public record of investments Pelosi and","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tempus-ai-inc-tem-best-172649397.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NVIW.SI",".IXIC","TQQQ","LU1861558580.USD","USJW.SI","PSQ","TEM","QLD","MNQmain","BK4121","TSYW.SI","LU1861559042.SGD","NQmain","SQQQ","BK4613","QID","USAW.SI","BK4611"],"gpt_icon":1},{"id":"2529986502","title":"BRIEF-Tempus AI Inc Announces Strategic Collaborations With AstraZeneca And Pathos","url":"https://stock-news.laohu8.com/highlight/detail?id=2529986502","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529986502?lang=en_us&edition=fundamental","pubTime":"2025-04-23 20:10","pubTimestamp":1745410241,"startTime":"0","endTime":"0","summary":"BRIEF-Tempus AI Inc Announces Strategic Collaborations With AstraZeneca And PathosApril 23 (Reuters) - Tempus AI TEM.O:TEMPUS AI INC - ANNOUNCES STRATEGIC COLLABORATIONS WITH ASTRAZENECA AND PATHOSTEM","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250423:nFWN3R1192:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2468319806.SGD","LU1057294990.SGD","SG9999013999.USD","SG9999001176.USD","IE0009355771.USD","LU0122379950.USD","LU0949170426.SGD","LU0557290698.USD","LU0640478417.SGD","SG9999001176.SGD","LU2089984988.USD","IE00B2B36J28.USD","LU0889566641.SGD","LU0661504455.SGD","LU0823399737.USD","TEM","LU2114397693.USD","IE00BJJMRZ35.SGD","LU1291159041.SGD","LU1481599808.USD","LU0784384876.USD","LU2089283258.USD","LU0757432116.USD","LU2091194634.USD","LU1261432733.SGD","LU1119994496.HKD","LU1814569148.SGD","LU1003076772.USD","LU0047473722.EUR","BK4611","LU1880407132.USD","LU0211326755.USD","AZN.UK","LU1323610961.USD","LU2089284900.SGD","LU0972486137.USD","LU0211327993.USD","LU1989771016.USD","LU0203345920.USD","LU0310800965.SGD","03165","LU1153584641.USD","LU0052756011.USD","LU1496350171.SGD","LU0957799991.USD","LU0575583348.USD","LU1267930573.SGD","LU0738911758.USD","LU2324357040.USD","LU0708994859.HKD"],"gpt_icon":0},{"id":"2529493595","title":"Recursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2529493595","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529493595?lang=en_us&edition=fundamental","pubTime":"2025-04-23 08:34","pubTimestamp":1745368440,"startTime":"0","endTime":"0","summary":"Salt Lake City, UT, April 22, 2025  -- Recursion , a leading clinical stage TechBio company decoding biology to radically improve lives, will present preliminary data during the 2025 Digestive Disease Week  meeting from its ongoing Phase 1b/2 clinical trial, TUPELO, which is evaluating the safety and preliminary activity of REC-4881 for the treatment of familial adenomatous polyposis . The data will be presented as a late-breaking oral presentation during the Research Forum session on Hereditary GI cancer syndromes on Sunday, May 4, 2025 in San Diego.“We are pleased that DDW has recognized the importance of our data in addressing the unmet needs of the FAP patient population, where no FDA-approved therapies currently exist,” said Najat Khan, PhD, Chief R&D Officer and Chief Commercial Officer at Recursion. “MEK 1/2 inhibition for the potential treatment of FAP was identified through our AI-powered Recursion OS platform, which analyzed cellular models of APC gene loss to uncover a poten","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/recursion-present-preliminary-clinical-data-003400160.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4539","BK4139","BK4609","BK4548","REC","BK4611","TRAE","RXRX"],"gpt_icon":1},{"id":"2529370437","title":"Crispr Therapeutics AG: Promising Growth with Casgevy Launch and Innovative Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2529370437","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529370437?lang=en_us&edition=fundamental","pubTime":"2025-04-22 19:35","pubTimestamp":1745321736,"startTime":"0","endTime":"0","summary":"Crispr Therapeutics AG (CRSP – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Kostas Biliou...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/crispr-therapeutics-ag-promising-growth-with-casgevy-launch-and-innovative-pipeline?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/crispr-therapeutics-ag-promising-growth-with-casgevy-launch-and-innovative-pipeline?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","AG","BK4556","BK4210","LU1861558580.USD","CRSP","LU1861559042.SGD","LENZ","BK4588","BK4611","BK4139","BK4585"],"gpt_icon":0},{"id":"2529571383","title":"Recursion Pharmaceuticals (RXRX) Stock Moves -1.64%: What You Should Know","url":"https://stock-news.laohu8.com/highlight/detail?id=2529571383","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529571383?lang=en_us&edition=fundamental","pubTime":"2025-04-22 05:50","pubTimestamp":1745272232,"startTime":"0","endTime":"0","summary":"Recursion Pharmaceuticals  closed the latest trading day at $5.41, indicating a -1.64% change from the previous session's end. The stock outperformed the S&P 500, which registered a daily loss of 2.36%. At the same time, the Dow lost 2.48%, and the tech-heavy Nasdaq lost 2.55%.Prior to today's trading, shares of the biotechnology company had lost 17.67% over the past month. This has lagged the Medical sector's loss of 9.83% and the S&P 500's loss of 5.6% in that time.Market participants will be closely following the financial results of Recursion Pharmaceuticals in its upcoming release. The company's earnings per share  are projected to be -$0.44, reflecting a 12.82% decrease from the same quarter last year. In the meantime, our current consensus estimate forecasts the revenue to be $20.15 million, indicating a 46.12% growth compared to the corresponding quarter of the prior year.Investors should also pay attention to any latest changes in analyst estimates for Recursion Pharmaceutical","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/recursion-pharmaceuticals-rxrx-stock-moves-215032641.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4548","BK4609","BK4139","RXRX","BK4611","BK4539"],"gpt_icon":1}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":32,"code":"91000000","status":"200"}]}}